EQL Pharma AB (publ)

OM:EQL Voorraadrapport

Marktkapitalisatie: SEK 1.6b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

EQL Pharma Toekomstige groei

Future criteriumcontroles 5/6

De verwachting is dat EQL Pharma de winst en omzet met respectievelijk 63.4% en 29.5% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 63.6% per jaar.

Belangrijke informatie

63.4%

Groei van de winst

63.6%

Groei van de winst per aandeel

Healthcare winstgroei33.0%
Inkomstengroei29.5%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt08 Aug 2024

Recente toekomstige groei-updates

Recent updates

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 22
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

Aug 12
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Jun 28
The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Apr 28
With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Feb 24
EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Dec 19
EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Jun 29
Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

Apr 29
Is EQL Pharma (NGM:EQL) Using Too Much Debt?

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Aug 10
We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Jun 07
EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

Apr 16
If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11
How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21
Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03
Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16
What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11
What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22
EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Winst- en omzetgroeiprognoses

OM:EQL - Toekomstschattingen van analisten en financiële gegevens uit het verleden (SEK Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
3/31/20264908951901
3/31/20254295417552
6/30/202429126-86-19N/A
3/31/202426423-78-11N/A
12/31/202324622-4719N/A
9/30/202325628-1112N/A
6/30/202327030-183N/A
3/31/202326031728N/A
12/31/2022403331529N/A
9/30/2022440393451N/A
6/30/2022419364163N/A
3/31/2022410322042N/A
12/31/202123319-649N/A
9/30/20211454-2440N/A
6/30/20211172-66-5N/A
3/31/202117910460N/A
12/31/202017217-1028N/A
9/30/202016316-520N/A
6/30/2020157145065N/A
3/31/2020723-117N/A
12/31/2019682-133N/A
9/30/201958-2-214N/A
6/30/201954-2-128N/A
3/31/201950-2-106N/A
12/31/201843-2110N/A
9/30/2018410N/AN/AN/A
6/30/2018350-22-3N/A
3/31/201832-1N/A-2N/A
12/31/2017301N/A-4N/A
9/30/2017300N/A-11N/A
6/30/2017260N/A-7N/A
3/31/2017240N/A1N/A
12/31/2016314N/A1N/A
9/30/2016295N/A10N/A
6/30/2016346N/A6N/A
3/31/2016357N/A2N/A
12/31/2015294N/A0N/A
9/30/2015261N/A-9N/A
6/30/201521-2N/A-7N/A
3/31/201519-5N/A-11N/A
12/31/201418-9N/A-12N/A
9/30/201419-11N/A-9N/A
6/30/201419-12N/A-8N/A
3/31/201420-11N/A-6N/A
12/31/201322-8N/A-6N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei EQL ( 63.4% per jaar) ligt boven de spaarquote ( 1.1% ).

Winst versus markt: De winst van EQL ( 63.4% per jaar) zal naar verwachting sneller groeien dan de Swedish markt ( 15.2% per jaar).

Hoge groeiwinsten: De winst van EQL zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van EQL ( 29.5% per jaar) zal naar verwachting sneller groeien dan de markt Swedish ( 1.4% per jaar).

Hoge groei-inkomsten: De omzet van EQL ( 29.5% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van EQL naar verwachting over 3 jaar hoog zal zijn

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y